IV Annual Russian–Chinese Pharmaceutical Forum to Take Place in Shanghai

On June 17, 2026, Shanghai will host the IV Annual Russian-Chinese Pharmaceutical Forum, one of the key events aimed at strengthening cooperation between Russia and China in the fields of pharmaceuticals and biotechnology. 

This year, the forum reaches a new level by being held for the first time at the venue of CPHI China, the world’s largest international pharmaceutical exhibition and business platform. CPHI China brings together manufacturers of pharmaceutical ingredients, finished dosage forms, equipment, and packaging, as well as leading industry experts from around the globe.

A new emphasis of the business program will be on enhancing regulatory dialogue. The first panel session, titled “Regulatory Aspects. Clinical Trials and Drug Registration in the Russian Federation and the EAEU: Dialogue with the Regulator,” will bring together representatives of regulatory authorities from Russia and China. From the Russian side, Alla Trapkova, Deputy Director General of the Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, will participate. The Chinese side will be represented by experts from the Chinese Society for Drug Regulation (CSDR) and representatives of the National Medical Products Administration (NMPA).

The session will address key regulatory topics, including clinical trials and drug registration, GMP and GCP requirements, as well as issues related to intellectual property and patent protection. Special attention will be given to opportunities for bringing Russian pharmaceutical products to the Chinese market, as well as to the position of Chinese regulators regarding Russia’s participation in international multicenter clinical trials with the aim of subsequent drug registration in EAEU countries.

The second session, “From Deals to Alliances: Case Studies in Cooperation, Clinical Trials, and Market Entry,” will focus on practical aspects of collaboration. Participants will discuss real-world examples of cooperation between the two countries and clinical trial implementation in Russia, including early-stage patient enrollment, as well as promising directions for pharmaceutical business development in Russia and China. Particular attention will be paid to international cooperation, from joint R&D and raw material supply to local production, technology transfer, and the commercialization of scientific developments. The speaker lineup for the second session is currently being finalized and will include representatives from leading Russian and Chinese pharmaceutical companies.

Traditionally, the forum will serve as a platform for establishing direct dialogue between business, regulators, and the scientific community of both countries, while also offering new formats of interaction and additional opportunities for partnership development. The organizers are preparing a range of special formats and additional activities that will be announced as part of the event program.

More information and registration are available on the official event website.